Opinion

Video

SPEARHEAD-1: Overview of Study Design, Key Efficacy, and Safety

Panelists discuss how afamitresgene autoleucel (afami-cel) demonstrated meaningful clinical activity in SPEARHEAD-1, with manageable cytokine release syndrome as the main safety concern.

Video content above is prompted by the following:

  • Briefly review the pivotal SPEARHEAD-1 trial that led to afami-cel’s approval.
  • Please review study design, key efficacy and safety (Tine et al, CTOS2022).
  • Please explain the role of targeting MAGE-A4.

Related Videos
2 expert is featured in this series.
4 experts are featured in this series.
2 experts in this video
Related Content
R. Lor Randall, MD, FACS
December 23rd 2024

Osteosarcoma Spheroid Models Provide Key Tool for Preclinical Drug Development

Gina Z. D’Amato, MD
February 9th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

FDA
November 25th 2024

FDA Approves Oral Solution of Imatinib for Certain Leukemias, Other Cancers

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors
December 29th 2022

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

Pimicotinib in Tenosynovial Giant Cell Tumor | Image Credit: © 2rogan - stock.adobe.com
November 12th 2024

Pimicotinib Meets ORR End Point in Tenosynovial Giant Cell Tumor

Fixed-Dose CAR T Cells and UB-TT170 in R/R Osteosarcoma | Image Credit: © MdBabul - stock.adobe.com
November 11th 2024

Fixed-Dose CAR T Cells Followed by Escalating UB-TT170 Increases Cytokine Levels in R/R Osteosarcoma